ORIGINAL ARTICLE

Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium

Gregory V. Schimizzi¹, Linda X. Jin¹, Jesse T. Davidson IV¹, Bradley A. Krasnick¹, Cecilia G. Ethun², Timothy M. Pawlik³, George Poultsides⁴, Thuy Tran⁴, Kamran Idrees⁵, Chelsea A. Isom⁵, Sharon M. Weber⁶, Ahmed Salem⁶, William G. Hawkins¹, Steven M. Strasberg¹, Maria B. Doyle¹, William C. Chapman¹, Robert C.G. Martin⁷, Charles Scoggins⁷, Perry Shen⁸, Harveshp D. Mogal⁸, Carl Schmidt⁹, Eliza Beal⁹, Ioannis Hatzaras¹⁰, Rivfka Shenoy¹⁰, Shishir K. Maithel² & Ryan C. Fields¹

¹Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, ²Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, ³Division of Surgical Oncology, Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, ⁴Department of Surgery, Stanford University Medical Center, Stanford, CA, ⁵Division of Surgical Oncology, Department of Surgery, Vanderbilt University Medical Center, Nashville, TN, ⁶Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, KY, ⁸Department of Surgery, Wake Forest University, Winston–Salem, NC, ⁹Division of Surgical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, and ¹⁰Department of Surgery, New York University, New York, NY, United States

Abstract

Background: Surgical resection is the cornerstone of curative-intent therapy for patients with hilar cholangiocarcinoma (HC). The role of vascular resection (VR) in the treatment of HC in western centres is not well defined.

Methods: Utilizing data from the U.S. Extrahepatic Biliary Malignancy Consortium, patients were grouped into those who underwent resection for HC based on VR status: no VR, portal vein resection (PVR), or hepatic artery resection (HAR). Perioperative and long-term survival outcomes were analyzed. **Results:** Between 1998 and 2015, 201 patients underwent resection for HC, of which 31 (15%) underwent VR: 19 patients (9%) underwent PVR alone and 12 patients (6%) underwent HAR either with (n = 2) or without PVR (n = 10). Patients selected for VR tended to be younger with higher stage disease. Rates of postoperative complications and 30-day mortality were similar when stratified by vascular resection status. On multivariate analysis, receipt of PVR or HAR did not significantly affect OS or RFS. **Conclusion:** In a modern, multi-institutional cohort of patients undergoing curative-intent resection for HC, VR appears to be a safe procedure in a highly selected subset, although long-term survival outcomes appear equivalent. VR should be considered only in select patients based on tumor and patient characteristics.

Received 13 May 2017; accepted 4 October 2017

Correspondence

Ryan C. Fields, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8109, St. Louis, MO, 63110-8109, United States. E-mail: fieldsr@wustl.edu

Introduction

In the United States, cholangiocarcinoma has a reported autopsy prevalence of 0.01-0.46% and an incidence of 1-2/100,000 population, although the incidence is much higher in Asia. 2,7,10

Surgical resection or transplant is the only potentially curative treatment of hilar cholangiocarcinoma, ¹⁸ however, the role of en bloc vascular resection remains controversial. ^{17,19} Therefore, the aim of the current study was to explore the safety and long-term

Selected for oral presentation at the AHPBA Annual Meeting 2017.

HPB 2017, **■**, 1-8

© 2017 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.

2 HPB

Table 1 Clinicopathologic variables associated with vascular resection in 201 patients after curative resection for hilar cholangiocarcinoma^a

cholangiocarcinoma ^a							
	No vascular resection		HA resection	p			
	n = 170	n = 19	n = 12				
Female (n, %)	101 (60)	9	6	0.515			
Age (x, sd)	66 (10)	62	52	p < 0.001			
Race				0.804			
White	129 (78)	15	10				
Black	12 (7)	2	1				
Asian	13 (8)	0	0				
BMI (x, sd) ^b	26 (6)	2	0				
		26	26	0.108			
Functional Status ^c							
Independent	152 (99)			0.367			
Partially Dependent	2 (1)	17	11				
ASA class		1	0				
1	2 (1)			0.928			
2	40 (28)	0	0				
3	94 (67)	7	3				
4	5 (4)	10	5				
Hypertension	90 (55)	1	0				
Diabetes Mellitus		12	10	0.060			
Managed with Oral Medications	14 (9)			0.549			
Insulin-Dependent	8 (5)	1	2				
Prior Cardiac Event	23 (14)	2	0				
Congestive Heart Failure	2 (0)	5	0	0.136			
Dyspnea	4 (3)	0	0	0.830			
Tobacco Use	42 (26)	0	0	0.687			
COPD	9 (6)	3	5	0.203			
Acute Kidney Injury	2 (1)	2	1	0.639			
Preoperative sepsis	11 (7)	0	0	0.830			
Preoperative jaundice	133 (80)	1	0	0.648			
Primary Sclerosing Cholangitis	4 (3)	15	11	0.592			
Ascites	6 (4)	0	1	0.310			
Preoperative stent placement		0	1	0.435			
Endoscopic stent only	68 (41)			0.142			
Percutaneous stent only	35 (21)	5	4				

Table 1 (continued)

		No vascular resection n = 170	resection		p
	Both	36 (21)	7	5	
	Neoadjuvant chemotherapy	6 (4)	1	3	0.002

^a Fields with missing data may not add to 100 percent.

outcomes of vascular resection during surgical treatment of hilar cholangiocarcinoma using data from a large cohort of patients from the U.S. Extrahepatic Biliary Malignancy Consortium.

Methods

The U.S. Extrahepatic Biliary Malignancy Consortium (USEBMC) is a collaboration of 10 high-volume, academic institutions, and includes Emory University, Johns Hopkins University, New York University, The Ohio State University, Stanford University, University of Louisville, University of Wisconsin, Vanderbilt University, Wake Forest University, and Washington University in St. Louis. All patients at participating institutions with HC who underwent resection with curative intent from 1998 to 2015 and had long-term follow-up data, including vital status and recurrence status, were included. Exclusion criteria included planned palliative or noncurative resections including bile duct resection only, missing data on vascular resection status, or incomplete follow-up data.

Standard demographic and clinicopathologic data were collected including age, sex, body mass index (BMI), American Society of Anesthesiologists (ASA) score, comorbidities (including history of hypertension, diabetes, COPD, congestive heart failure, renal failure, chronic steroid use, and tobacco use), tumor-related signs and symptoms, type of surgery and tumor-specific characteristics. In particular, data were collected on presence of jaundice or ascites and preoperative biliary drainage. Data on treatment-related variables, such as type of surgery and receipt of lymphadenectomy and intraoperative estimated blood loss (EBL), were also collected. Pathology review was performed by experienced GI pathologists at each institution, and staging was assigned as per American Joint Committee on Cancer (AJCC) 7th edition guidelines. Institutional Review Board approval was obtained at each institution prior to data collection.

^b BMI indicates body mass index; ASA class, American Society of Anesthesiologists classification.

^c Functional status: Independent, the patient does not require assistance from another person for activities of daily living. This includes a person who is able to function independent with prosthetics, equipment or devices. Partially dependent, the patient requires some assistance from another person for activities of daily living. This includes a person who utilizes prosthetics, equipment or devices but still requires some assistance from another person for activities of daily living.

Download English Version:

https://daneshyari.com/en/article/8722764

Download Persian Version:

https://daneshyari.com/article/8722764

<u>Daneshyari.com</u>